TD Cowen analyst Josh Jennings reiterated a Buy rating on Boston Scientific (BSX) with a $61 price target, despite the stock's year-to-date decline of over 52%. The analyst expressed confidence in the company's resilience and its ability to meet Q2 2026 revenue and EPS guidance, noting that lowered expectations make targets more achievable. Boston Scientific, a medical device company, is expected by analysts to see more than 65% upside from its current level.

Citigroup Global Markets Holdings Inc. is offering autocallable senior notes tied to the S&P 500 Futures 35% Edge Volatility 6% Decrement Index (USD) ER, due July 10, 2036. These notes do not pay interest, can be automatically redeemed early, and expose holders to full downside risk if the index falls below a 60% barrier. The underlying index is highly risky due to its leveraged exposure, volatility targeting, and a persistent 6% per annum decrement, which can significantly reduce returns.

One Plus One Wealth Management LLC significantly reduced its stake in Kratos Defense & Security Solutions (KTOS) by 64.6% in the first quarter, holding shares worth $1.16 million. This move comes amid substantial insider selling of KTOS stock, totaling $11.7 million in the last 90 days. Despite these reductions in holdings, analysts maintain a "Moderate Buy" consensus rating with an average price target of $101.35 for Kratos Defense & Security Solutions.

Ionis' drug Tryngolza has received FDA approval for severe hypertriglyceridaemia (sHTG), significantly expanding its target patient population from 3,000 to around 3 million people in the US. This approval is crucial for the drug to meet its blockbuster sales expectations, as it has demonstrated the ability to reduce triglycerides and the risk of acute pancreatitis. To support this broader market, Ionis has substantially lowered the drug's annual list price from $595,000 to $40,000.

Jefferies Financial Group Inc. is offering Senior Autocallable Leveraged Barrier Notes due July 20, 2029, linked to the worst-performing of the S&P 500 Index and the SPDR S&P MidCap 400 ETF Trust (MDY). These notes offer a 125.00% upside participation rate and an automatic early call feature with a payment of $1,130.00 if called on July 19, 2027. Investors face potential principal loss if the worst-performing underlying falls below 70% of its initial value, and all payments are unsecured and subject to Jefferies' credit risk.

This article presents the "Enterprise value to EBIT forward" for Jumia Technologies AG (NYSE: JMIA). It appears to be a financial data point from TradingView, indicating a key valuation metric for the company. The content primarily focuses on the financial overview of JMIA within the TradingView platform.

Sterling Bank of Asia has chosen Infosys Finacle's Software-as-a-Service (SaaS) platform for its digital transformation, incorporating Finacle Core Banking, Customer Data Hub, Trade Finance, and Origination solutions. This collaboration aims to enhance customer and employee experiences, reduce operational complexity through automation, and support future growth. Leveraging the SaaS model, Sterling Bank will benefit from simplified technology management, faster innovation cycles, and scalable cloud-hosted infrastructure, enabling them to remain compliant and focus on strategic initiatives.

This article features Stanley Bergman, the chief executive officer of Henry Schein Inc., as one of the "Notables in Health Care 2021" recognized by Crain's New York Business. Further details about his contributions are likely contained in the full article, which is not provided here.

This article identifies three real estate stocks – Crown Castle Inc. (CCI), Zillow Group Inc. (Z), and Braemar Hotels & Resorts (BHR) – as oversold opportunities with RSI values near or below 30. It provides recent company news, price action, and contributing factors for each, suggesting they could offer potential value for investors this quarter.

Germany's Merck KGaA announced its acquisition of U.S. biotech firm Bio-Techne Corp for $11.3 billion, offering $73 per share, a 24% premium over Bio-Techne's closing price. This strategic move aims to expand Merck's presence in the life sciences market by gaining access to Bio-Techne's research reagents, proteins, antibodies, and analytical instruments. The deal, Merck's largest life sciences acquisition since 2014, is expected to close by late 2026 or early 2027 and will be financed through a combination of cash and debt.